Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Celecoxib

FDA-approved product (capsule, oral), marketed as Celebrex, Celecoxib, Elyxyb and 1 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Celecoxib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Ankylosing spondylitis
  • Cancer
  • Colorectal neoplasm
  • Dysmenorrhea
  • Familial adenomatous polyposis
  • Familial adenomatous polyposis 1
  • Hemorrhage
  • Juvenile idiopathic arthritis
  • Migraine disorder
  • Neoplasm
  • Osteoarthritis
  • Pain
  • Peptic ulcer
  • Peptic ulcer disease
  • Rheumatic disease
  • Rheumatoid arthritis
  • and 2 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents; Coxibs
FDA pharmacologic class
Nonsteroidal Anti-inflammatory Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli25.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis87.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 1 of 1 lab record
Open Celecoxib in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Celecoxib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety of Celecoxib in Patients With Crohn's Disease

    NCT00177866 · start 2003-12

    Registered record
    Registry ID
    NCT00177866
    Conditions
    Crohn's Disease
    Interventions
    Celebrex; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2003-12
    Completion
    2010-06
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionCelebrex; placebo
    PhasePhase 4
    Registry statusTerminated

  • Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer

    NCT00061906 · start 2003-01

    Registered record
    Registry ID
    NCT00061906
    Conditions
    Head and Neck Cancer
    Interventions
    celecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-01
    Completion
    2006-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    Interventioncelecoxib
    PhasePhase 2
    Registry statusCompleted

  • Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib

    NCT00365313 · start 2002-08

    Registered record
    Registry ID
    NCT00365313
    Conditions
    Arthritis; Bleeding Ulcer
    Interventions
    celecoxib, esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-08
    Completion
    2005-06
    Enrolment
    273

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthritis; Bleeding Ulcer
    Interventioncelecoxib, esomeprazole
    PhasePhase 3
    Registry statusCompleted

  • Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer

    NCT00022399 · start 2002-04-25

    Registered record
    Registry ID
    NCT00022399
    Conditions
    Prostate Cancer
    Interventions
    celecoxib; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-04-25
    Completion
    2005-01-31
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventioncelecoxib; Placebos
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib

    NCT00582660 · start 2001-12

    Registered record
    Registry ID
    NCT00582660
    Conditions
    Colorectal Adenoma; Colorectal Carcinoma
    Interventions
    Celecoxib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-12
    Completion
    2008-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Adenoma; Colorectal Carcinoma
    InterventionCelecoxib; Placebo
    PhasePhase 2
    Registry statusCompleted